MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: Results of a Phase 2 study in growth hormone-deficient adults

Abstract

Objective: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modifed growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH defciency (GHD). This study's objective is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and effcacy of MOD-4023 administered once-weekly in GHD adults. Design: 54 adults with GHD currently treated with daily GH were normalized and randomized into 4 weekly dosing cohorts of MOD-4023 at 18.5%, 37%, 55.5% or 123.4% of individual cumulative weekly molar hGH dose. The study included 2 stages: Stage A assessed the effectiveness and PK/PD profles of the 4 dosing regimens of MOD-4023. Stage B was an extension period of once-weekly MOD-4023 administration (61.7% molar hGH content) to collect further safety data and confrm the results from Stage A. Results: Dose-dependent response was observed for both PK and PD data of weekly MOD-4023 treatment. Insulin-like growth factor I (IGF-I) SDS levels were maintained within normal range. The 18.5% cohort was discontinued due to low effcacy. MOD-4023 was well tolerated and exhibited favorable safety profle in all dose cohorts. The reported adverse events were consistent with known GH-related side effects. Conclusions: Once-weekly MOD-4023 administration in GHD adults was found to be clinically effective while maintaining a favorable safety profle and may obviate the need for daily injections. Weekly GH injections may improve compliance and overall outcome. The promising results achieved in this Phase 2 study led to a pivotal Phase 3 trial, which is currently ongoing.